Xu Q, Wang J, Sun Y, Lin Y, et al. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial. J Clin Oncol 2022 Feb 22:JCO2102091. doi: 10.1200/JCO.21.02091.
PMID: 35192397